Related Experiment Video

Updated: May 31, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Correlation of insulin resistance, beta cell function and insulin sensitivity with serum sFas and sFasL in newly

Hemant Kumar1, Manish Mishra, Surabhi Bajpai

  • 1Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005, India.

Acta Diabetologica
|June 23, 2011
PubMed

Insights

Type 2 diabetes is linked to increased insulin resistance and pancreatic beta cell dysfunction, indicated by elevated apoptotic markers like sFas. These markers correlate with insulin resistance and beta cell function in diabetic patients.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Immunology

Background:

  • Type 2 diabetes mellitus (T2DM) is characterized by pancreatic beta cell dysfunction and insulin resistance.
  • Glucotoxicity, lipotoxicity, and oxidative stress contribute to T2DM pathogenesis.
  • Apoptosis plays a role in the progression of T2DM.

Purpose of the Study:

  • To compare circulating soluble apoptotic markers (sFas and sFas-L) with insulin resistance (HOMA-IR) and beta cell function (HOMA-%B, HOMA-%S) in newly diagnosed T2DM patients and healthy individuals.
  • To investigate the relationship between apoptotic markers and metabolic parameters in T2DM.

Main Methods:

  • Serum levels of sFas, sFas-L, insulin, TNF-α, and IL-6 were measured in 94 T2DM patients and 60 healthy controls.
  • Biochemical parameters including lipids were quantified.
  • Insulin resistance and beta cell function were calculated using the Homeostatic Model Assessment (HOMA) calculator.
  • Flow cytometry and ELISA were used for marker quantification.

Main Results:

  • T2DM patients exhibited significantly higher levels of serum insulin, TNF-α, IL-6, sFas, and HOMA-IR compared to healthy subjects.
  • Conversely, sFas-L, HOMA-%S, and HOMA-%B were significantly lower in T2DM patients.
  • Serum sFas positively correlated with HOMA-IR and negatively with HOMA-%B in T2DM.
  • Serum sFas-L showed a negative correlation with HOMA-IR and a positive correlation with HOMA-%B.
  • Multivariate analysis indicated HOMA-IR significantly influences sFas and sFas-L levels.

Conclusions:

  • Pancreatic beta cell dysfunction and increased insulin resistance in T2DM are associated with elevated apoptotic markers.
  • sFas and sFas-L may serve as potential indicators of apoptosis and disease progression in T2DM.
  • These findings highlight the role of apoptosis in the pathophysiology of T2DM.

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...